For the quarter ended December 2024, Stryker (SYK) reported revenue of $6.44 billion, up 10.7% over the same period last year. EPS came in at $4.01, compared to $3.46 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $6.35 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +3.62%, with the consensus EPS estimate being $3.87.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expe ...

Stryker (SYK) came out with quarterly earnings of $4.01 per share, beating the Zacks Consensus Estimate of $3.87 per share. This compares to earnings of $3.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.62%. A quarter ago, it was expected that this medical device maker would post earnings of $2.78 per share when it actually produced earnings of $2.87, delivering a surprise of 3.24%.Over the last four quarters, the compan ...

Exhibit 99.1 STRYKER REPORTS 2024 OPERATING RESULTS AND 2025 OUTLOOK MedSurg and Neurotechnology net sales of $3.9 billion and $13.5 billion increased 10.6% in the quarter, 11.1% in constant currency, and increased 11.1% in the full year, 11.6% in constant currency. Organic net sales increased 10.1% and 11.2% in the quarter and full year including 8.5% and 9.5% from increased unit volume and 1.6% and 1.7% from higher prices. Portage, Michigan - January 28, 2025 - Stryker (NYSE:SYK) reported operating result ...

Core Insights - Stryker has entered into a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, forming a new entity called VB Spine, LLC [1][2] - The transaction aims to enhance the focus and growth potential of the spinal implants business as an independent company [2][3] - VB Spine will have exclusive access to Stryker's Mako Spine and Copilot technologies for its spinal procedures, fostering a strategic partnership [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually with innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - Viscogliosi Brothers is a family-owned investment firm focused on the neuro-musculoskeletal industry, having founded and grown 42 businesses across more than 80 countries since its establishment in 1999 [6] - Barings, LLC is a financial partner in this transaction, managing over $421 billion in assets as of December 31, 2024 [7] Transaction Details - The sale includes a binding offer to acquire Stryker's spinal implants business in France, pending employee consultations and regulatory requirements [3] - The transaction is expected to close in the first half of 2025, with both Stryker and VB Spine continuing to operate separately until then [3]

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein’s decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker’s Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. “I want to thank Glenn for his performance drive, strong business partnership, and exce ...

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Cons ...

Stryker Corporation (SYK) is scheduled to release fourth-quarter 2024 results on Jan. 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 3.24%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $3.87 per share, indicating an increase of 11.9% year over year.The consensus mark for revenues is pinned at $6.35 billion, implying growth of 9.2% from the prior-year reported fig ...

Stryker Corporation (NYSE: SYK ) is a fantastic company with a long history of successfully commercializing innovative products in the medical device industry. Across its diversified business, it has shown steady growth in revenues, earnings, and FCF over multiple decades. ThisI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and ...

Analysts on Wall Street project that Stryker (SYK) will announce quarterly earnings of $3.87 per share in its forthcoming report, representing an increase of 11.9% year over year. Revenues are projected to reach $6.35 billion, increasing 9.2% from the same quarter last year.The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ove ...

Stryker Corporation (SYK) recently inked a definitive agreement to acquire all the issued and outstanding shares of common stock of Inari Medical, Inc. (NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.Through the acquisition of Inari Medical, Stryker is likely to expand its portfolio and provide life-saving solutions to patients with peripheral vascular diseases.Likely Trend of SYK Stock Following the NewsFollowing the announcement, shares of th ...